CeriBell (NASDAQ:CBLL) Shares Gap Up – Here’s What Happened

CeriBell (NASDAQ:CBLL)’s share price gapped up prior to trading on Monday . The stock had previously closed at $21.03, but opened at $22.09. CeriBell shares last traded at $21.27, with a volume of 7,158 shares.

Wall Street Analyst Weigh In

A number of brokerages have commented on CBLL. Canaccord Genuity Group restated a “buy” rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen boosted their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $32.60.

CeriBell Price Performance

The business’s 50 day simple moving average is $22.46.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million. As a group, research analysts anticipate that CeriBell will post -2.46 EPS for the current year.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc purchased a new position in CeriBell during the 4th quarter valued at about $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell during the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell during the 4th quarter valued at about $37,000. BNP Paribas Financial Markets purchased a new position in CeriBell during the 4th quarter valued at about $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in CeriBell during the 4th quarter valued at about $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.